Nussbaum Ran
SEC insider (Form 3/4/5 filer). CIK 0001609805. Director at LB PHARMACEUTICALS INC (LBRX) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 3, 2026. Located in NEW YORK, NY.
Companies Nussbaum Ran has filed insider reports for
- LB PHARMACEUTICALS INC (LBRX): Director
- Keros Therapeutics, Inc. (KROS): Director, 10% Owner
Nussbaum Ran
CIK: 0001609805
Transaction Breakdown
Open Market Buys (P)1 (20.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (60.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (20.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 3, 2026LBRX
LB PHARMACEUTICALS INC
AwardDirectStock Option (Right to Buy)
10K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
ConversionIndirect411.7K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
PurchaseIndirect1M shares at avg. $15.00$15.0M - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
AwardDirectStock Option (Right to Buy)
22.4K shares- - Jun 4, 2025KROS
Keros Therapeutics, Inc.
AwardDirect5.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  LBRX LB PHARMACEUTICALS INC | Award Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Conversion | 411,681 | - | - | Indirect |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase | 1,000,000 | $15.00 | $15,000,000 | Indirect |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award Stock Option (Right to Buy) | 22,449 | - | - | Direct |
| Jun 4, 2025 |  KROS Keros Therapeutics, Inc. | Award | 5,250 | - | - | Direct |
1-5 of 5 transactions